RSS Feeds
Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
- Nelson Leung, MD;
- Sundararaman Swaminathan, MBBS;
- Iftikhar Ahmed, MD;
- James T. McCarthy, MD;
- Robert C. Albright, DO;
- Mark R. Pittelkow, MD;
- Noel M. Caplice, MD, PhD; and
- Matthew D. Griffin, MB BCh
IN RESPONSE:
We appreciate Dr. Hellman's interest and comments. We, too, have noted that nearly half of our patients with nephrogenic fibrosing dermopathy had gadolinium exposure before the development of their disease. However, a similar number of our 50 dialysis patients were also exposed to gadolinium—some exposed on several occasions—without any evidence of the condition. This seems to support our hypothesis that multiple factors are involved in the pathogenesis of nephrogenic fibrosing dermopathy. We are currently investigating the possible interaction between gadolinium and erythropoietin in this disease.
Nelson Leung, MD
Sundararaman Swaminathan, MBBS
Iftikhar Ahmed, MD
James T. McCarthy, MD
Robert C. Albright, DO
Mark R. Pittelkow, MD
Noel M. Caplice, MD, PhD
Matthew D. Griffin, MB BCh
Mayo Clinic College of Medicine
Rochester, MN 55905
Article and Author Information
-
Potential Financial Conflicts of Interest: None disclosed.
